Pioneering Research Examines the Role of Your Gut in Multiple Sclerosis

Stephanie K Tankou, MD, PhD
Is a crucial cause of multiple sclerosis (MS) residing in your gut? Stephanie K Tankou, MD, PhD, Assistant Professor of Neurology at The Corinne Goldsmith Dickinson Center for Multiple Sclerosis, is conducting research designed to prove that specific gut bacteria generate inflammation that underlies MS.
“At some point in our life, we can become exposed to various environmental stressors that can lead to profound changes in the gut microbe composition and put someone at risk for developing MS,” she says.
Trillions of microbes called the human microbiome are living in each human. The largest community of microbes, called the gut microbiome, exist in the gut. They are essential for the proper development of your immune system and your brain.
“Studies have shown that a disturbance in the normal composition of these gut microbes can lead to many diseases, including MS,” she says.
Within a healthy individual’s gut, there is a delicate balance of pro-inflammatory and anti-inflammatory bacteria. Conditions favoring an overgrowth of the pro-inflammatory bacteria can trigger inflammation in the gut leading to the breakdown of the gut barrier, also known as leaky gut. In individuals with a leaky gut, microbes in the gut can enter the bloodstream, where they will activate various immune cells, including inflammatory cells that will destroy myelin—a sheath that forms around nerves—in the brain and spinal cord of MS patients.
Several studies, including ones conducted at the Tankou Lab found that mice infused with gut microbes taken from MS patients develop more severe inflammation in the brain and spinal cord than mice that received gut microbes from healthy subjects.
“These results suggest that alterations found in the gut microbe composition of an MS patient significantly contributes to the disease,” she says. “So, the question is what changes do we need to introduce in the gut microbiome of MS patients to stop the disease?”
Dr. Tankou joined the Center staff in 2019. While she sees MS patients, she spends most of her time in her research lab.
“I became interested in the gut microbiome because one of the biggest hurdles we run into with MS, or any neurological disease, is we do not have access to the disease tissue, to the brain or the spinal cord,” she explains. “Consider the gut microbiome as a remote control for your brain. I can control the level of inflammation in the brain of my MS patients by changing the composition of their gut microbes.”
To further her theory, Dr. Tankou’s lab found that an antibiotic called vancomycin, when given orally to mice with an MS-like disease, suppresses inflammation in the brain and spinal cord. Her study showed that administering vancomycin orally causes significant changes in the mice gut microbe composition, leading to an increase in the abundance of anti-inflammatory bacteria in their gut, which decreased inflammation in the brain and spinal cord of these mice.
For her current, ongoing study, Dr. Tankou received funding from the Doris Duke Charitable Foundation to examine the impact of vancomycin on newly diagnosed MS patients between the ages of 18 and 50 who have not taken any MS treatment. Participants receive either vancomycin or a placebo as well as provide blood and stool samples.
“We are hopeful that vancomycin will cause a dramatic shift in the gut microbe composition of these MS patients that will suppress inflammation in the brain,” says Dr. Tankou. The findings from this vancomycin trial could lead to the development of the first “bugs as drugs” for the prevention and treatment of MS. “Bugs as drugs” refers to communities of gut derived bacteria with anti-inflammatory properties that can be used to suppress inflammation and disease progression in MS.
Dr. Tankou maintains that “bugs as drugs” will be safer than the current MS treatments approved by the Food and Drug Administration, which are all based on chemical structures and come with a range of side effects, whereas using microbes means nothing foreign will be introduced into patients. “We expect a new ‘bug as drugs’ therapy to be just as effective as drugs we are currently using,” she says.
The promise and hope that Dr. Tankou’s pioneering lab offers will position the Center as an institutional leader in understanding what causes MS, as well as developing novel microbiome-based therapies for preventing and treating all forms of the chronic disease.
By Kenneth Bandler, a multiple sclerosis patient, advocate, and member of The Corinne Goldsmith Dickinson Center for Multiple Sclerosis Advisory Board